Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies
Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies
'